BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, Sammartino JC, Sun R, Vlachiotis S, Bergami F, Kumagai-Braesch M, Andréll J, Zhang Z, Xue Y, Wenzel EV, Calzolai L, Varani L, Rezaei N, Chavoshzadeh Z, Baldanti F, Hust M, Hammarström L, Marcotte H, Pan-Hammarström Q. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun 2022;13:2670. [PMID: 35562366 DOI: 10.1038/s41467-022-30340-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Kyaw MH, Spinardi J, Zhang L, Oh HML, Srivastava A. Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines. Hum Vaccin Immunother 2023;19:2165856. [PMID: 36727201 DOI: 10.1080/21645515.2023.2165856] [Reference Citation Analysis]
2 Liu J, He Q, Gao F, Bian L, Wang Q, An C, Song L, Zhang J, Liu D, Song Z, Li L, Bai Y, Wang Z, Liang Z, Mao Q, Xu M. Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice. Emerg Microbes Infect 2023;12:e2143283. [PMID: 36377297 DOI: 10.1080/22221751.2022.2143283] [Reference Citation Analysis]
3 Deng X, Zhao Y, Wang S, He H, Chen Z, Zhou Y, Yan R, Tang X, Zhu Y, Xu X. Assessing COVID-19 Vaccine Booster Hesitancy Using the Modified 5C Scale in Zhejiang Province, China: A Cross-Sectional Study. Vaccines (Basel) 2023;11:706. [PMID: 36992290 DOI: 10.3390/vaccines11030706] [Reference Citation Analysis]
4 Xiao C, Ren Z, Zhang B, Mao L, Zhu G, Gao L, Su J, Ye J, Long Z, Zhu Y, Chen P, Su X, Zhou T, Huang Y, Chen X, Xie C, Yuan J, Hu Y, Zheng J, Wang Z, Lou J, Yang X, Kuang Z, Zhang H, Wang P, Liang X, Luo OJ, Chen G. Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults. Nat Aging 2023. [DOI: 10.1038/s43587-023-00379-0] [Reference Citation Analysis]
5 Tang R, Zheng H, Wang BS, Gou JB, Guo XL, Chen XQ, Chen Y, Wu SP, Zhong J, Pan HX, Zhu JH, Xu XY, Shi FJ, Li ZP, Liu JX, Zhang XY, Cui LB, Song ZZ, Hou LH, Zhu FC, Li JX; CanSino COVID-19 Study Group. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir Med 2023:S2213-2600(23)00049-8. [PMID: 36898400 DOI: 10.1016/S2213-2600(23)00049-8] [Reference Citation Analysis]
6 Lu C, Zhang Y, Liu X, Hou F, Cai R, Yu Z, Liu F, Yang G, Ding J, Xu J, Hua X, Cheng X, Pan X, Liu L, Lin K, Wang Z, Li X, Lu J, Zhang Q, Li Y, Hu C, Fan H, Liu X, Wang H, Jia R, Xu F, Wang X, Huang H, Zhao R, Li J, Cheng H, Jia W, Yang X. Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine. Antiviral Res 2023;212:105556. [PMID: 36871919 DOI: 10.1016/j.antiviral.2023.105556] [Reference Citation Analysis]
7 Dash NR, Barqawi HJ, Obaideen AA, Al Chame HQ, Samara KA, Qadri R, Eldesouki S. COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. J Epidemiol Glob Health 2023;13:67-90. [PMID: 36795274 DOI: 10.1007/s44197-023-00090-8] [Reference Citation Analysis]
8 Sauré D, O'Ryan M, Torres JP, Zuñiga M, Soto-Rifo R, Valiente-Echeverría F, Gaete-Argel A, Neira I, Saavedra V, Acevedo ML, Archila C, Acuña F, Rain M, Basso LJ. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study. Lancet Microbe 2023;4:e149-58. [PMID: 36716754 DOI: 10.1016/S2666-5247(22)00290-7] [Reference Citation Analysis]
9 Hayashi N. Rapid screening methods for universal binding peptide aptamers against SARS-CoV-2 variant spikes, including omicron variants, and their application to diagnostic and therapeutic agents.. [DOI: 10.21203/rs.3.rs-2609957/v1] [Reference Citation Analysis]
10 Santos da Silva E, Servais JY, Kohnen M, Arendt V, Gilson G, Staub T, Seguin-Devaux C, Perez-Bercoff D. Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. Curr Issues Mol Biol 2023;45:1741-61. [PMID: 36826057 DOI: 10.3390/cimb45020112] [Reference Citation Analysis]
11 Azevedo PO, Hojo-Souza NS, Faustino LP, Fumagalli MJ, Hirako IC, Oliveira ER, Figueiredo MM, Carvalho AF, Doro D, Benevides L, Durigon E, Fonseca F, Machado AM, Fernandes AP, Teixeira SR, Silva JS, Gazzinelli RT. Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. NPJ Vaccines 2023;8:15. [PMID: 36781862 DOI: 10.1038/s41541-023-00616-y] [Reference Citation Analysis]
12 Mao S, Li S, Zhang Y, Long L, Peng J, Cao Y, Mao JZ, Qi X, Xin Q, San G, Ding J, Jiang J, Bai X, Wang Q, Xu P, Xia H, Lu L, Xie L, Kong D, Zhu S, Xu W. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. Nano Today 2023;48:101730. [PMID: 36570700 DOI: 10.1016/j.nantod.2022.101730] [Reference Citation Analysis]
13 Chevaisrakul P, Lumjiaktase P, Kietdumrongwong P, Chuatrisorn I, Chatsangjaroen P, Phanuphak N. Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program. Sci Rep 2023;13:763. [PMID: 36641523 DOI: 10.1038/s41598-023-28101-5] [Reference Citation Analysis]
14 Wen C, Liu W, He Z, Liu C. Research on emergency management of global public health emergencies driven by digital technology: A bibliometric analysis. Front Public Health 2022;10:1100401. [PMID: 36711394 DOI: 10.3389/fpubh.2022.1100401] [Reference Citation Analysis]
15 Zhang L, Yang J, Lai C, Wan L, Xiong S, Kong W, Liu Z, Yu P, Chen M, Mai W, Khan SA, Deng M, Chen L, Lei Y, Zhou Q, Yu N, Li P, Chen Z, Ji T. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients. Front Immunol 2022;13:1042784. [PMID: 36700230 DOI: 10.3389/fimmu.2022.1042784] [Reference Citation Analysis]
16 Li P, Wang W, Tao Y, Tan X, Li Y, Mao Y, Gao L, Feng L, Zhan S, Sun F. Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. Chin Med J (Engl) 2023;136:24-33. [PMID: 36723872 DOI: 10.1097/CM9.0000000000002567] [Reference Citation Analysis]
17 Nam J, Park H, Bang Y, Kwon SP, Kwak W, Park S, Roh G, Bae S, Kim J, Kwak HW, Kim Y, Yoo S, Kim D, Keum G, Bang E, Hong S. Analysis of vaccine-induced immune responses according to the immunization sequences of mRNA and protein vaccines.. [DOI: 10.21203/rs.3.rs-2361251/v1] [Reference Citation Analysis]
18 Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, Jin YQ, Hou JW, Zhang J, Yang T, Hussein S, ElDein MS, Lei ZH, Zhang H, Shao S, Liu ZM, Liu N, Zheng X, Su JG, Yang SS, Cong X, Tan Y, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Shen FJ, Wu JJ, Han ZB, Du LF, Tang F, Chen S, Ma ZJ, Zheng F, Hou YN, Li XY, Li X, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. Signal Transduct Target Ther 2023;8:20. [PMID: 36596779 DOI: 10.1038/s41392-022-01295-2] [Reference Citation Analysis]
19 Wang Q, Ye SB, Zhou ZJ, Song AL, Zhu X, Peng JM, Liang RM, Yang CH, Yu XW, Huang X, Yu J, Qiu Y, Ge XY. Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization. J Med Virol 2023;95:e28407. [PMID: 36519597 DOI: 10.1002/jmv.28407] [Reference Citation Analysis]
20 Sedaghat N, Etemadifar M, Lotfi N, Sayahi F, Chitsaz A, Salari M, Ghasemi Movaghar A. Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity. Front Immunol 2023;14:952911. [PMID: 36895555 DOI: 10.3389/fimmu.2023.952911] [Reference Citation Analysis]
21 Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, Aeemjinda R, Khanarat N, Vichaiwattana P, Klinfueng S, Thongmee T, Katanyutanon A, Thanasopon W, Arayapong J, Withaksabut W, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens. Int J Infect Dis 2023;126:64-72. [PMID: 36427701 DOI: 10.1016/j.ijid.2022.11.022] [Reference Citation Analysis]
22 Sim W, Kang H, Jung J, Lee J, Ko GY, Park HS, Choi J, Park K, Oh EJ. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study. Front Immunol 2023;14:1120556. [PMID: 36936965 DOI: 10.3389/fimmu.2023.1120556] [Reference Citation Analysis]
23 Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, Rabaan AA, Alhumaid S, Mutair AA, Iqhrammullah M, Al-Tawfiq JA, Mohaini MA, Alsalman AJ, Tuli HS, Chakraborty C, Harapan H. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health 2023;16:4-14. [PMID: 36446204 DOI: 10.1016/j.jiph.2022.11.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
24 He Q, Sun S, Chen X, Hu Z, Zhang Y, Peng H, Fu YX, Yang J, Chen L. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages. J Clin Med 2022;12. [PMID: 36614948 DOI: 10.3390/jcm12010146] [Reference Citation Analysis]
25 Li J, Li X, Wang E, Yang J, Li J, Huang C, Zhang Y, Chen K. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. Vaccines (Basel) 2022;10. [PMID: 36560521 DOI: 10.3390/vaccines10122111] [Reference Citation Analysis]
26 Chia TRT, Young BE, Chia PY. The Omicron-transformer: Rise of the subvariants in the age of vaccines. Ann Acad Med Singap 2022;51:712-729. [DOI: 10.47102/annals-acadmedsg.2022294] [Reference Citation Analysis]
27 Lau CS, Thundyil J, Oh MLH, Phua SK, Liang YL, Li Y, Huo J, Huang Y, Zhang B, Xu S, Aw TC. Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster. Antibodies (Basel) 2022;11. [PMID: 36412836 DOI: 10.3390/antib11040070] [Reference Citation Analysis]
28 Forte E, Des Soye BJ, Melani RD, Hollas MAR, Kafader JO, Sha BE, Schneider JR, Kelleher NL. Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. J Proteome Res 2022;21:2987-97. [PMID: 36343328 DOI: 10.1021/acs.jproteome.2c00514] [Reference Citation Analysis]
29 Bergami F, Arena F, Sammartino JC, Ferrari A, Zavaglio F, Zelini P, Paolucci S, Comolli G, Percivalle E, Lilleri D, Cassaniti I, Baldanti F. Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers. Vaccines 2022;10:1809. [DOI: 10.3390/vaccines10111809] [Reference Citation Analysis]
30 Junyan Jin, Xiuwen Wang, Raphael Carapito, Christiane Moog, Bin Su. Advances in Research on COVID-19 Vaccination for People Living with HIV. Infectious Diseases & Immunity 2022;2. [ DOI: 10.1097/ID9.0000000000000065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Luangdilok S, Wanchaijiraboon P, Pakvisal N, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Sainamthip P, Suntronwong N, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Teeyapun N, Tanasanvimon S. Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine. Vaccines 2022;10:1613. [DOI: 10.3390/vaccines10101613] [Reference Citation Analysis]
32 DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity 2022:S1074-7613(22)00500-3. [PMID: 36182669 DOI: 10.1016/j.immuni.2022.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lu C, Zhang Y, Liu X, Hou F, Cai R, Yu Z, Liu F, Yang G, Ding J, Xu J, Hua X, Pan X, Liu L, Lin K, Wang Z, Li X, Lu J, Zhang Q, Li Y, Hu C, Fan H, Liu X, Wang H, Jia R, Xu F, Wang X, Huang H, Zhao R, Li J, Cheng H, Jia W, Yang X. Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.. [DOI: 10.1101/2022.09.06.506714] [Reference Citation Analysis]
34 González S, Olszevicki S, Gaiano A, Baino ANV, Regairaz L, Salazar M, Pesci S, Marín L, Martínez VVG, Varela T, Ceriani L, Garcia E, Kreplak N, Navarro A, Estenssoro E, Marsico F. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study. Lancet Reg Health Am 2022;13:100316. [PMID: 35872665 DOI: 10.1016/j.lana.2022.100316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chantasrisawad N, Puthanakit T, Kornsitthikul K, Jaru-ampornpan P, Tawan M, Matapituk P, Sophonphan J, Anugulruengkitt S, Tangsathapornpong A, Katanyutanon A. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster. Vaccine: X 2022. [DOI: 10.1016/j.jvacx.2022.100221] [Reference Citation Analysis]
36 Ertl HCJ, Currie SL, Luber AD. Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health. Front Immunol 2022;13:985382. [DOI: 10.3389/fimmu.2022.985382] [Reference Citation Analysis]
37 Walker MR, Podlekareva D, Johnsen S, Leerhøy B, Fougeroux C, Søgaard M, Salanti A, Ditlev SB, Barfod L. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. Viruses 2022;14:1861. [DOI: 10.3390/v14091861] [Reference Citation Analysis]
38 Marcotte H, Hammarström L, Pan-Hammarström Q. Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster. Signal Transduct Target Ther 2022;7:294. [PMID: 35995763 DOI: 10.1038/s41392-022-01146-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Chiuppesi F, Zaia JA, Faircloth K, Johnson D, Ly M, Karpinski V, La Rosa C, Drake J, Marcia J, Acosta AM, Dempsey S, Taplitz RA, Zhou Q, Park Y, Ortega Francisco S, Kaltcheva T, Frankel PH, Rosen S, Wussow F, Dadwal S, Diamond DJ. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. iScience 2022;25:104745. [PMID: 35846380 DOI: 10.1016/j.isci.2022.104745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Hajissa K, Mussa A, Karobari MI, Abbas MA, Ibrahim IK, Assiry AA, Iqbal A, Alhumaid S, Mutair AA, Rabaan AA, Messina P, Scardina GA. The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. Vaccines 2022;10:1346. [DOI: 10.3390/vaccines10081346] [Reference Citation Analysis]
41 Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Zarębska-Michaluk D, Hu C, Brzdęk M, Flisiak R, Rzymski P. COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines (Basel) 2022;10:1223. [PMID: 36016111 DOI: 10.3390/vaccines10081223] [Reference Citation Analysis]
43 Park S, Gatchalian KK, Oh H. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel. Cureus 2022. [DOI: 10.7759/cureus.27323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Zhang Z, He Q, Zhao W, Li Y, Yang J, Hu Z, Chen X, Peng H, Fu Y, Chen L, Lu L. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains. JCM 2022;11:4164. [DOI: 10.3390/jcm11144164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
45 Wang Y, Tian Q, Ye L. The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells. Front Cell Infect Microbiol 2022;12:953022. [DOI: 10.3389/fcimb.2022.953022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 da Silva ES, Kohnen M, Gilson G, Staub T, Arendt V, Hilger C, Servais J, Charpentier E, Domingues O, Snoeck CJ, Ollert M, Seguin-devaux C, Perez-bercoff D. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. IJMS 2022;23:7675. [DOI: 10.3390/ijms23147675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Geisen UM, Rose R, Neumann F, Ciripoi M, Vullriede L, Reid HM, Berner DK, Bertoglio F, Hoff P, Hust M, Longardt AC, Lorentz T, Rios Martini G, Saggau C, Schirmer JH, Schubert M, Sümbül M, Tran F, Voß M, Zeuner R, Morrison PJ, Bacher P, Fickenscher H, Gerdes S, Peipp M, Schreiber S, Krumbholz A, Hoyer BF. Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccination.. [DOI: 10.1101/2022.07.01.22277143] [Reference Citation Analysis]
48 Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Yorsaeng R, Vichaiwattana P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Thongmee T, Auphimai C, Nilyanimit P, Wanlapakorn N, Sudhinaraset N, Poovorawan Y. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Vaccines 2022;10:1071. [DOI: 10.3390/vaccines10071071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Möhlendick B, Čiučiulkaitė I, Elsner C, Anastasiou OE, Trilling M, Wagner B, Zwanziger D, Jöckel K, Dittmer U, Siffert W. Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections. Front Immunol 2022;13:907343. [DOI: 10.3389/fimmu.2022.907343] [Reference Citation Analysis]
50 Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Yorsaeng R, Vichaiwattana P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Thongmee T, Auphimai C, Nilyanimit P, Wanlapakorn N, Sudhinaraset N, Poovorawan Y. Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine.. [DOI: 10.1101/2022.06.16.22276480] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Wang Y, Abolhassani H, Hammarström L, Pan-Hammarström Q. SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects. Acta Biochim Biophys Sin (Shanghai) 2022;54:836-46. [PMID: 35713311 DOI: 10.3724/abbs.2022071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Li Q, Wang Y, Sun Q, Knopf J, Herrmann M, Lin L, Jiang J, Shao C, Li P, He X, Hua F, Niu Z, Ma C, Zhu Y, Ippolito G, Piacentini M, Estaquier J, Melino S, Weiss FD, Andreano E, Latz E, Schultze JL, Rappuoli R, Mantovani A, Mak TW, Melino G, Shi Y. Immune response in COVID-19: what is next? Cell Death Differ 2022;29:1107-22. [PMID: 35581387 DOI: 10.1038/s41418-022-01015-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]